{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}],"title":"nCR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}],"title":"VGPR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"}]}],"title":"PR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"MR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}],"title":"SD"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"13"}]}],"title":"ORR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"description":"Number of participants with each disease response category utilizing the Blade criteria:\n\n* Complete Response (CR): Defined as negative serum and urine immunofixation and a bone marrow aspirate with \\< 5% plasma cells.\n* Near Complete Response (nCR): Defined as negative serum and urine paraprotein, positive serum and/or urine immunofixation, and a bone marrow aspirate with \\< 5% plasma cells.\n* Very Good Partial Response (VGPR): Defined as negative serum and urine paraprotein with positive serum and/or urine immunofixation; or a 90% decrease in serum paraprotein with urine paraprotein \\< 100 mg/24 hours.\n* Partial Response (PR): Defined as a 50-89% decrease in serum paraprotein.\n* Minimal Response (MR): Defined as a 25-49% decrease in serum paraprotein.\n* Stable Disease (SD): Defined as not falling into any other response category.\n* Overall response rate (ORR): Total of CR, nCR, VGPR, and PR.","groups":[{"description":"Cyclophosphamide and filgrastim will be given to mobilize peripheral blood stem cells. Leukapheresis will be performed to collect peripheral blood from which activated marrow infiltrating lymphocytes will be produced. A melphalan conditioning regimen will be used prior to autologous stem cell transplant, and the MILs product will be administered on Days 3 and 4.","id":"OG000","title":"ASCT + MILs"},{"description":"Cyclophosphamide and filgrastim will be given to mobilize peripheral blood stem cells. Leukapheresis will be performed to collect peripheral blood from which activated marrow infiltrating lymphocytes will be produced. A melphalan conditioning regimen will be used prior to autologous stem cell transplant, and the MILs product will be administered on Days 3 and 4. The allogeneic myeloma vaccine will be administered on Days 21, 60, 180, and 300.","id":"OG001","title":"ASCT + MILs + Vaccine"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only participants who had ASCT were evaluated for response. Three participants on the ASCT + MILs arm and two participants on the ASCT + MILs + vaccine arm were removed from study prior to ASCT and were therefore not evaluable for this outcome.","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Response Rates by Blade Criteria","type":"PRIMARY","unitOfMeasure":"Participants"}